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I npatient glycemic control and hypoglycemia are issues withwell deserved increased attention in recent years. Prominent
guidelines and technical reviews have been published,1–3 and a
recent, randomized controlled trial demonstrated the superiority
of basal bolus insulin regimens compared to sliding-scale regi-
mens.4 Effective glycemic control for inpatients has remained
elusive in most medical centers. Recent reports5–7 detail clinical
inertia and the continued widespread use of sliding-scale sub-
cutaneous insulin regimens, as opposed to the anticipatory,
physiologic ‘‘basal-nutrition-correction dose’’ insulin regimens
endorsed by these reviews.
Inpatient glycemic control faces a number of barriers,
including fears of inducing hypoglycemia, uneven knowledge
and training among staff, and competing institutional and
patient priorities. These barriers occur in the background of an
inherently complex inpatient environment that poses unique
challenges in maintaining safe glycemic control. Patients fre-
quently move across a variety of care teams and geographic
locations during a single inpatient stay, giving rise to multiple
opportunities for failed communication, incomplete handoffs,
and inconsistent treatment. In addition, insulin requirements
may change dramatically due to variations in the stress of illness,
exposure tomedications that effect glucose levels, and varied forms
of nutritional intake with frequent interruption. Although insulin is
recognized as one of the medications most likely to be associated
with adverse events in the hospital, many hospitals do not have
protocols or order sets in place to standardize its use.
A ‘‘Call to Action’’ consensus conference,8,9 hosted by the
American Association of Clinical Endocrinologists (AACE) and
the American Diabetes Association (ADA), brought together
many thought leaders and organizations, including representa-
tion from the Society of Hospital Medicine (SHM), to address
these barriers and to outline components necessary for success-
ful implementation of a program to improve inpatient glycemic
control in the face of these difficulties. Institutional insulin man-
agement protocols and standardized insulin order sets (sup-
ported by appropriate educational efforts) were identified as key
interventions. It may be tempting to quickly deploy a generic in-
sulin order set in an effort to improve care. This often results in
mediocre results, due to inadequate incorporation of standardi-
zation and guidance into the order set and other documentation
tools, and uneven use of the order set.
The SHM Glycemic Control Task Force (GCTF) recommends
the following steps for developing and implementing successful
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protocols and order sets addressing the needs of
the non–critical care inpatient with diabetes/
hyperglycemia.
c Form a steering committee for this work, and
assess the current processes of care.
c Identify best practices and preferred regimens to
manage diabetes and hyperglycemia in the hospital.
c Integrate best practices and preferred institutional
choices into an inpatient glycemic control protocol.
Crystallize your protocol into a one page summary.
c Place guidance from your protocol into the flow of
work, by integrating it into standardized subcuta-
neous insulin order sets and other documentation
and treatment tools.
c Monitor the use of your order sets and protocol.
Intervene actively on nonadherents to your proto-
col and those with poor glycemic control, and
revise your protocol/order sets as needed.
IDENTIFYING AND INCORPORATING KEY CONCEPTS
AND BEST PRACTICES
A protocol is a document that endorses specific
monitoring and treatment strategies in a given
institution. This potentially extensive document
should provide guidance for transitions, special
situations (like steroids and total parenteral nutri-
tion [TPN]) and should outline preferred insulin
regimens for all of the most common nutritional
situations. One of the most difficult parts of creat-
ing a protocol is the assimilation of all of the im-
portant information on which to base decisions.
Your protocol and order set will be promoting a
set of clinical practices. Fortunately, the current
‘‘best practice’’ for non–critical care hyperglycemic
patients has been summarized by several authori-
tative sources,1–3,8–11 including references from
the SHM Glycemic Task Force published in this
supplement.4,12
Table 1 summarizes the key concepts that
should be emphasized in a protocol for subcuta-
neous insulin management in the hospital. We
recommend embedding guidance from your pro-
tocol into order sets, the medication administra-
tion record, and educational materials. Although
the details contained in a protocol and order set
might vary from one institution to another, the
key concepts should not. The remainder of this ar-
ticle provides practical information about how
these concepts and guidance for how preferred in-
sulin regimens should be included in these tools.
Appendices 1 and 2 give examples of an institu-
tional one-page summary protocol and subcuta-
neous insulin order set, respectively.
Standardize the Monitoring of Blood Glucose Values and
Glucosylated Hemoglobin
Guidance for the coordination of glucose testing,
nutrition delivery, and insulin administration,
should be integrated into your protocols, and
order sets. For non–critical care areas, the minimal
frequency for blood glucose monitoring for
patients who are eating is before meals and at
bedtime. For the patient designated ‘‘nothing by
mouth’’ (NPO) or the patient on continuous tube
feeding, the type of nutritional/correction insulin
used should drive the minimum frequency (every
4-6 hours if rapid acting analog insulins [RAA-I] are
used, and every 6 hours if regular insulin is used).
Directions for administering scheduled RAA-I im-
mediately before or immediately after nutrition
delivery should be incorporated into protocols,
order sets, and medication administration records.
Unfortunately, having this guidance in the order sets
and protocols does not automatically translate into
TABLE 1
Key Concepts To Emphasize in Protocols and Order Sets for
Subcutaneous Insulin Use in Non–Critically Ill Inpatients
1. Establish a target range for blood glucose levels.
2. Standardize monitoring of glucose levels and assessment of long-term control
(HbA1c).
3. Incorporate nutritional management.
4. Prompt clinicians to consider discontinuing oral antihyperglycemic
medications.
5. Prescribe physiologic (basal-nutrition-correction) insulin regimens.
a. Choose a total daily dose (TDD).
b. Divide the TDD into physiologic components of insulin therapy and
provide basal and nutritional/correction separately.
c. Choose and dose a basal insulin.
d. Choose and dose a nutritional (prandial) insulin
i. Match exactly to nutritional intake (see Table 2).
ii. Include standing orders to allow nurses to hold nutritional insulin for
nutritional interruptions and to modify nutritional insulin depending
on the actual nutritional intake.
e. Add correction insulin
i. Match to an estimate of the patients insulin sensitivity using
prefabricated scales.
ii. Use the same insulin as nutritional insulin.
6. Miscellaneous
a. Manage hypoglycemia in a standardized fashion and adjust regimen to
prevent recurrences.
b. Provide diabetes education and appropriate consultation.
c. Coordinate glucose testing, nutrition delivery, and insulin administration.
d. Tailor discharge treatment regimens to the patient’s individual
circumstances and arrange for proper follow-up.
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its being carried out in the real world. Wide variabili-
ty in the coordination of glucose monitoring, nutri-
tional delivery, and insulin administration is
common, so monitoring the process to make sure
the protocol is followed is important.
Obtaining a glucosylated hemoglobin (HbA1c)
level is important in gauging how well the
patient’s outpatient regimen is maintaining glyce-
mic control, distinguishing stress hyperglycemia
from established diabetes, and guiding the inpati-
ent approach to glycemic control. ADA guide-
lines2,3 endorse obtaining HbA1c levels of inpatients
if these levels are not already available from the
month prior to admission.
Establish a Target Range for Blood Glucose
in Non–Critical Care Areas
It is important to adopt a glycemic target that is
institution-wide, for critical care areas and non–
critical care areas alike. Your glycemic target need
not be identical to the ADA/AACE glycemic tar-
gets, but should be similar to them.
Examples of institutional glycemic targets for
non–critical care areas:
c Preprandial target 90-130 mg/dL, maximum ran-
dom glucose <180 mg/dL (ADA/AACE consensus
target)
c 90-150 mg/dL (a target used in some hospitals)
c Preprandial target 90-130 mg/dL for most patients,
100-150 mg/dL if there are hypoglycemia risk fac-
tors, and <180 mg/dL if comfort-care or end-of-life
care (a more refined target, allowing for customiza-
tion based on patient characteristics).
Your multidisciplinary glycemic control steer-
ing committee should pick the glycemic target it
can most successfully implement and disseminate.
It is fine to start with a conservative target and
then ratchet down the goals as the environment
becomes more accepting of the concept of tighter
control of blood glucose in the hospital.
Although the choice of glycemic target is
somewhat arbitrary, establishing an institutional
glycemic target is critical to motivate clinical
action. Your committee should design interven-
tions, for instances when a patient’s glycemic tar-
get is consistently not being met, including an
assignment of responsibility.
Prompt Clinicians to Consider Discontinuing Oral Agents
Oral antihyperglycemic agents, in general, are dif-
ficult to quickly titrate to effect, and have side
effects that limit their use in the hospital. In con-
trast, insulin acts rapidly and can be used in vir-
tually all patients and clinical situations, making it
the treatment of choice for treatment of hypergly-
cemia in the hospital.3,11,12 In certain circum-
stances, it may be entirely appropriate to continue
a well-controlled patient on his or her prior out-
patient oral regimen. It is often also reasonable to
resume oral agents in some patients when prepar-
ing for hospital discharge.
Incorporate Nutritional Management
Because diet is so integral to the management of
diabetes and hyperglycemia, diet orders should be
embedded in all diabetes or insulin-related order
sets. Diets with the same amount of carbohydrate
with each meal should be the default rule for
patients with diabetes. Nutritionist consultation
should be considered and easy to access for patients
with malnutrition, obesity, and other common con-
ditions of the inpatient with diabetes.
Access Diabetes Education and Appropriate Consultation
Diabetes education should be offered to all hyper-
glycemic patients with normal mental status,
complete with written materials, a listing of com-
munity resources, and survival skills. Consultation
with physicians in internal medicine or endocri-
nology for difficult-to-control cases, or for cases in
which the primary physician of record is not fa-
miliar with (or not adherent to) principles of inpa-
tient glycemic management, should be very easy




Physiologic insulin use is the backbone of the
recommended best practice for diabetes and
hyperglycemia management in the hospital. The
principles of such regimens are summarized else-
where in this supplement.12 These principles will
not be reiterated in detail here, but the major con-
cepts that should be integrated into the protocols
and order sets will be highlighted.
Choose a Total Daily Dose
Clinicians need guidance on how much subcuta-
neous insulin they should give a patient. These
doses are well known from clinical experience and
the published literature. The fear of hypoglycemia
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usually results in substantial underdosing of insu-
lin, or total avoidance of scheduled insulin on
admission. Your team should provide guidance for
how much insulin to start a patient on when it is
unclear from past experience how much insulin
the patient needs. Waiting a few days to see how
much insulin is required via sliding-scale-only
regimens is a bad practice that should be discour-
aged for patients whose glucose values are sub-
stantially above the glycemic target. The total
daily dose (TDD) can be estimated in several dif-
ferent ways (as demonstrated in Appendix 1 and
2), and protocols should make this step very clear
for clinicians. Providing a specific location on the
order set to declare the TDD may help ensure this
step gets done more reliably. Some institutions
with computer physician order entry (CPOE) pro-
vide assistance with calculating the TDD and the
allocation of basal and nutritional components,
based on data the ordering physician inputs into
the system.
Select and Dose a Basal Insulin
Your protocol should describe how the TDD
should be divided between basal and nutritional
insulin. We generally recommend 50% of the TDD
be given as basal insulin, with the other 50%
administered on a scheduled basis to cover glyce-
mic excursions from nutritional intake. The 50/50
rule is simple and generally works well, and
should be widely promoted. However, there are
exceptions to this rule that should be incorporated
into your full protocol and educational programs.
The order set should have separate steps for
ordering basal insulin, nutritional insulin, and cor-
rection insulin. The advantage to providing these
insulin components separately is that it allows
them to be independently manipulated (eg, if a
patient is unable to tolerate a meal, nutritional in-
sulin is held, but basal insulin and correction in-
sulin are continued).
The SHM GCTF specifically endorses long act-
ing insulin (glargine and detemir) as the preferred
basal insulin in the hospital setting, thus discoura-
ging the use of neutral protamine Hagedorn
(NPH) insulin and fixed combination insulin for-
mulations (Table 2). In the absence of randomized
controlled trials demonstrating superiority of the
glargine or detemir to NPH insulin in the hospital,
this endorsement deserves some further explana-
tion. Although we believe that correctly dosed
TABLE 2
Society of Hospital Medicine Glycemic Control Task Force Recommendations: Preferred Insulin Regimens for Different Nutritional Situations
Nutritional situation Necessary insulin components Preferred regimen*
NPO (or clear liquids) Basal insulin: 50% of TDD. Nutritional insulin: None. Basal insulin: glargine given once daily or detemir given twice daily.
Nutritional insulin: None. Correctional insulin: Regular insulin q 6 hours
or RAA insulin q 4 hours. Other comments: Dextrose infusion (e.g., D5
containing solution at 75-150 cc/hour) recommended when nutrition is
held. An IV insulin infusion is preferred for management of prolonged
fasts or fasting type 1 diabetes patients.
Eating meals Basal insulin: 50% of TDD. Nutritional insulin: 50% of TDD,
divided equally before each meal.
Basal insulin: glargine given once daily or detemir given twice daily.
Nutritional insulin: RAA insulin with meals. Correctional insulin: RAA
insulin q AC and HS (reduced dose at HS).
Bolus tube feeds Basal insulin: 40% of TDD. Nutritional insulin: 60% of the TDD,
divided equally before each bolus feed.
Basal insulin: glargine given once daily or detemir given twice daily.
Nutritional insulin: RAA insulin with each bolus. Correctional insulin: RAA
insulin with each bolus.
Continuous tube feeds Basal insulin: 40% (conservative) of TDD. Nutritional insulin:
60% of the TDD in divided doses.
Basal insulin: glargine given once daily or detemir given twice daily.
Nutritional insulin: RAA insulin q 4 hours or regular insulin q 6 hours.
Correctional insulin: Should match nutritional insulin choice.
Parenteral nutrition Insulin is usually given parenterally, with the nutrition Initially, a separate insulin drip allows for accurate dose-finding. Then, 80%
of amount determined as TDD using drip is added to subsequent TPN
bags as regular insulin. Use correctional subcutaneous insulin doses
cautiously, in addition.
Abbreviations: D5, dextrate 5% solution; HS, at bedtime; IV, intravenous; NPO, ‘‘nothing by mouth’’; q 4 hours, every 4 hours; q 6 hours, every 6 hours; q AC, before every meal; RAA, rapid-acting analog; TDD,
total daily dose; TPN, total parenteral nutrition.
* These are the preferred regimens for most patients in these situations by consensus of the SHM Glycemic Control Task Force. Alternate regimens may appropriately be preferred by institutions or physicians to
meet the needs of their own patient population. RAA insulins include lispro, aspart, and glulisine.
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NPH containing insulin regimens can attain effec-
tive and safe glycemic control in the hospital set-
ting, it is more difficult to standardize their use
and adjust for fluctuations in nutritional intake.
Glargine and detemir have much less pronounced
spikes in their effect than NPH, rendering them
relatively ‘‘peakless’’ in comparison. This pharma-
cokinetic profile allows for continued dosing with
minimal or no correction when nutrition intake is
variable, and allow for consistent reinforcement of
the basal-nutritional-correction insulin concept.
There are some caveats to this general recom-
mendation. First, patients who are well controlled
on home regimens with NPH basal insulin can
(and sometimes should) stay on the regimen that
has worked well for them. However, extra vigilance
in reducing the dose for reductions in nutrition is
required, because NPH is generally used to cover
both nutritional and basal requirements. Second,
extensive experience with glargine and detemir
are not available in obstetric populations. They
are not U.S. Food and Drug Administration (FDA)
approved for use in pregnant patients and for-
mally carry a Class C rating, whereas NPH insulin
has been used safely in obstetric populations for
decades. Third, the insulin regimen used as an
inpatient is not necessarily the preferred regimen
to prescribe at discharge: cost, patient preferences,
HbA1c level, and other factors should be consid-
ered in making this choice.
Select and Dose a Nutritional (Prandial) Insulin
The step for ordering nutritional insulin should
assist the clinician in matching the insulin to the
type of nutrition that the patient is receiving. For
example, rapid-acting insulin analogs are pre-
ferred over regular insulin in the eating patient, in
view of their more physiologic profile, which
averts the insulin stacking that can occur with
regular insulin. If regular insulin is used as the
preferred institutional choice for eating patients,
the lunchtime dose should be reduced or elimi-
nated altogether, to eliminate insulin stacking.
Table 2 outlines the SHM GCTF preferred regi-
mens for different nutritional situations.
There should be a standing order for nutri-
tional insulin to be held when nutrition is inter-
rupted, whether intentional or unintentional.
Patients with interrupted tube feedings could have
standing orders for a dextrose infusion to replace
the tube feeding carbohydrate load and prevent
hypoglycemia. Ideally, there should also be a
standing order allowing for real-time management
of the patient with uncertain nutritional intake.
For example, when a patient’s premeal assessment
reveals that she may not tolerate the meal, the
patient should be allowed to attempt to eat, and
then the nutritional insulin should be given after
the meal, in proportion to the amount of food
that was eaten. This type of order will require sig-
nificant nursing education and process redesign in
many hospitals, but is essential for matching
nutritional insulin to actual intake.
Add Correction Insulin
There is no convincing evidence for the benefit of
correction (sliding-scale) insulin in the inpatient
setting, although a randomized trial demonstrat-
ing the superiority of basal/nutritional insulin
regimens to ‘‘sliding-scale only’’ regimens did
incorporate a correction insulin scale as an
adjunct to the superior basal/nutritional regimen.4
The SHM GCTF again emphasizes that control of
hyperglycemia should be proactive and anticipa-
tory of insulin needs, rather than reactive to
hyperglycemia. Nonetheless, unexpected hypergly-
cemic excursions are common, and the use of cor-
rection insulin remains a pervasive and arguably
logical practice. If correction insulin is used, it
should be ordered as a separate step after consid-
ering basal and nutrition insulin needs. The doses
of scheduled insulin should be adjusted regularly
if correction insulin is consistently being required.
Ideally, the prescriber should choose a prefor-
matted corrective insulin scale, based on the
patient’s insulin sensitivity (Appendix 2). There
should be a prompt to use the same type of insu-
lin that is being used for nutritional insulin, and
there should be instructions that this insulin is
given in addition to the basal and nutritional insu-
lin to correct for hyperglycemia. Nocturnal correc-
tion-dose scales should be reduced in the eating
patient.
Even after limiting insulin regimens to those
in Table 2, multidisciplinary glycemic control
teams are still left with several options within
these SHM-preferred regimens. We recommend
that your team choose a single, institutionally-pre-
ferred basal-nutritional-correction insulin combi-
nation for each situation.
Choosing one preferred option for these situa-
tions is advantageous because:
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1. You can communicate preferred regimens more
simply and succinctly to all staff.
2. You eliminate all inappropriate choices for insulin
regimens for that situation, as well as some other
less preferred, but acceptable choices.
3. You can encourage regimens that are most eco-
nomical (by promoting the insulin regimens that
reflect your hospital formulary choices).
4. Staff members can become very familiar with a
few regimens, instead of being confused by a mul-
titude of them. They can identify variations from
your preferred choices and target these patients
for extra scrutiny and actions should they fail to
meet glycemic targets.
Although virtually every institution can pro-
vide specific guidance on insulin management in
a protocol, there are tradeoffs inherent in how re-
strictive you can be in pushing these preferred
choices in your order sets. Should you eliminate
alternate basal or nutritional insulin choices from
your order sets? As you integrate more and more
of your preferred algorithm and regimens into
your order set, you will gain incremental improve-
ment in the standardization of inpatient insulin
management. However, you reduce not only vari-
ability in ordering, but also the choices available
to your prescribers and patients, and in effect you
are pushing the providers to use an insulin regi-
men that often differs from the patient’s outpati-
ent regimen. If your institution is not yet ready to
go with a single preferred insulin, simply listing
your preferred insulin first with the annotation
‘‘preferred’’ can be enough to increase the use of
the preferred insulin.
We endorse building the most protocol-driven,
proscriptive, insulin order set that the Glycemic
Control Steering Committee believes their medical
staff will accept. There are some caveats to this
endorsement. First, there must be extra efforts on
the ‘‘backend’’ of the admission, to ensure that
the antihyperglycemic regimen is tailored to the
unique needs of the patient (this is discussed fur-
ther below). Second, a protocol-driven approach is
not a substitute for a good educational program
for health care providers or well-informed clinical
judgment. Education should reinforce major con-
cepts driving the protocol and should also high-
light ‘‘exceptions to the rule.’’ Variance from the
protocol endorsed choices should be allowed (and
even encouraged) when the variance is driven by
patient factors (as opposed to provider whim).
Learning from this variance is a key concept in
refining protocols. Education ideally should not be
limited to only protocol-endorsed choices, as staff
should be familiar with the full range of antihy-
perglycemia regimens seen in inpatient and out-
patient settings.
Special Situations
Most of the preferred regimens for different situa-
tions are outlined in Table 2 in a straightforward
manner, and can be depicted in your protocols
and order sets in the same way. Some conditions
have enough complexity, however, that you will
have difficulty placing all of the details into your
one-page protocol and order set. Details should
be placed on your more detailed protocol, and
educational programs should include the topics
outlined below. Although insulin infusion is often
the option that would provide the most reliable
and expedient control of hyperglycemia in these
special situations, it is an option not available in
many non–critical care settings. Therefore, the dis-
cussion is limited to subcutaneous insulin control
regimens.
Patient on Continuous Tube Feeding
The SHM GCTF endorses glargine or detemir as
the basal insulin of choice for this setting. The
nutritional and correction insulin of choice is
either an RAA-I every 4 hours (q4h), or regular in-
sulin every 6 hours (q6h). We endorse this choice
because it retains the basal-nutritional-correction
dose concept, generally allows for continued basal
insulin use if the tube feedings become inter-
rupted, and is amenable to building a consistent
institutional protocol.
There are some important caveats to this rec-
ommendation. First, realize that almost any regi-
men that provides a stable insulin supply would
be acceptable, and many institutions will use glar-
gine or detemir to cover both basal and nutri-
tional needs. The downside to using large boluses
of long-acting insulin in this clinical situation is
that any unexpected interruption of the feedings
will necessitate prolonged infusions of dextrate
10% solution (D10) to avoid hypoglycemia
Second, because of the glycemic load inherent
in tube feedings, maintenance of glycemic control
in the setting of enteral feeding may be best man-
aged by providing a higher percentage of the TDD
as nutritional insulin. In these cases, ratios of
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basal to nutritional insulin of 40:60, or even less
basal insulin, may be appropriate.
Glucocorticoid Therapy
High-dose glucocorticoids are strongly associated
with increased insulin requirements. The degree
of hyperglycemia induced by steroids varies signif-
icantly from patient to patient, and the pattern of
hyperglycemia will vary depending on the pattern
of steroid administration. The general principle to
keep in mind is that the hyperglycemia induced
by a steroid dose will peak 8-12 hours after it is
given, so insulin regimens to address this should
take this effect into account. For example, giving a
long-acting basal insulin like glargine to accom-
modate the hyperglycemic effect of a steroid bolus
given in the morning would be inappropriate
because the steroid effect would wane and then
disappear overnight, leading to insulin-induced
hypoglycemia. NPH insulin can be ideal in this
setting, either by itself, or by layering it on top of
an existing regimen.
Another caveat: glucocorticoids exert their pre-
dominate effect on insulin sensitivity in muscle
(as opposed to the liver), and as a result, have
their most notable effect on postprandial glucose.
For this reason, the best insulin regimens for this
situation may use proportionally less basal insulin
and more nutritional insulin. One common regi-
men calls for keeping the basal insulin dose the
same as the preglucocorticoid dose, while escalat-
ing the RAA insulin dose at lunch and dinner.
Given the complexities of covering steroid-
induced hyperglycemia and its high prevalence in
certain populations (such as transplantation
patients and patients undergoing chemotherapy),
this would be an excellent area on which to focus
expertise. Examples include routine endocrinology
consultation, intervention by a special glycemic
control team, or incorporating routine glucose
monitoring and triggers for initiating insulin infu-
sion into the protocols for chemotherapy and
transplantation patients.
Regiment the Management of Hypoglycemia
Hypoglycemia is defined by the ADA as a blood
glucose of 70 mg/dL or less, based on the physio-
logic changes that can occur at this glucose level,
even in subjectively asymptomatic patients.3 Pro-
tocols for management of hypoglycemia should be
linked to your diabetes/hyperglycemia protocols.
There are many hypoglycemia protocols available
for review in the SHM Glycemic Control Resource
Room and Glycemic Control Implementation
Guide.10 Some common themes for effective
implementation stand out. First, the protocols
need to walk the balance between simplicity of
use, and the need to provide instructions that will
provide guidance in a variety of patient situations.
Second, the protocols need to be nurse driven, so
that nurses can initiate treatment without waiting
for a physician order. Third, education and
instruction regarding recognition of risk factors,
and avoidance of hypoglycemia are needed to
support a successful protocol. Importantly, any
hypoglycemic event should lead to a reconsidera-
tion of the current anti-hyperglycemic regimen so
that future events can be prevented.
Plan for Discharge and Provide Guidance
for the Transition
Your institution should have policies and proce-
dures outlining all the steps needed to complete
the important transition out of the hospital. At a
minimum, this planning should include adequate
education (including a learner assessment), appro-
priate follow-up, referral to community resources,
and a discharge glycemic control regimen that is
tailored to the educational, financial, and motiva-
tional profile of a patient. The more your inpatient
insulin management is driven by protocol, the
more likely it is the patient will be on an inpatient
treatment plan that differs from their outpatient
regimen; therefore, it is even more important to
plan this transition carefully and reliably.
Communicating the accurate hyperglycemia
related diagnosis and related problems to the pri-
mary care provider is important for good care,
perhaps even more so for patients who had hyper-
glycemia while hospitalized without a prior diag-
nosis of diabetes. Some centers place a prompt
for hyperglycemia related diagnosis in the order
set and/or discharge paperwork, to remind the
clinician to convey the diagnosis to the primary
provider, and to encourage more complete docu-
mentation. Improved documentation can also
improve the business case for glycemic control,
along with other strategies outlined elsewhere in
this supplement.13
Transitions in care (including transitions out
of the hospital and off of infusion insulin) are
discussed in more detail14,15 elsewhere in this
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supplement. The principles outlined in these
references should be incorporated into your insti-
tutional protocol. Briefly, not all patients require
or are capable of intensive basal-bolus regimens
upon discharge. The HbA1c can be very valuable
in arriving at the optimal outpatient regimen.14
The capacities and preferences of the patient and
the context of his or her outpatient care envi-
ronment (including the preferences of the
primary care provider) must be taken into consid-
eration as an outpatient management program is
planned.
PULLING IT ALL TOGETHER: MAKE SURE YOUR
PROTOCOL/ORDER SET IS EASY TO USE
AND WIDELY UTILIZED
When standardizing hospital management of dia-
betes and hyperglycemia, we recommend building
the full protocol first, then crystallizing the proto-
col into a one-page summary that can be widely
disseminated. The protocol guidance is then
incorporated into the order set and nursing medi-
cal administration record (MAR). Again, we
recommend the most proscriptive and protocol-
driven order set feasible within the constraints of
medical staff support. The example order set in
Appendix 2 illustrates this approach along with
other desirable features:
1. Check-box simplicity on when to order appropri-
ate glucose monitoring.
2. Prompt for the proper hyperglycemia-related di-
agnosis.
3. Prompts to document diagnosis and to order
HbA1c level.
4. Use of encouraged insulin terminology: basal,
prandial (or nutritional), and correction. Lan-
guage is a powerful thing, and just getting staff
to use these terms goes a long way toward the
more physiologic prescribing of insulin.
5. Statement/reminder of a glycemic goal.
6. Prompts and contact information for appropriate
consultation.
7. Elimination of unapproved abbreviations (such
as U for units).
8. Stating both generic and brand names of insulin
preparations.
9. Important timing cues for administration of
insulin.
10. Several correction-dose scales suitable for differ-
ent insulin sensitivities. One size does NOT fit all.
11. Incorporation of a simple hypoglycemia protocol
into the order set.
12. Insulin dosing guidelines available at the point of
care (in this case, on the back of the order set).
Additional nursing-specific cues (such as an
admonition to never mix glargine insulin with
other types of insulin) can also be included in the
MAR whenever glargine is ordered.
Once you have protocols and order sets to
guide providers, you need to assure that they are
used for the majority of hyperglycemic patients.
Educational programs should introduce your
interventions and the rationale for them. In order
to make your method the default method of care,
your team should survey all preprinted or CPOE
insulin order sets of your institution. A review of
postoperative, transfer, and admission order sets
that all services use may reveal a half-dozen or
more embedded sliding-scale insulin order sets
that should be removed, with prompts to use the
standardized insulin order set being placed in
their stead.
Computerized order sets present both chal-
lenges and opportunities. Wording limitations and
the scrolling nature can make concepts less clear,
yet there is a capability for incorporating a hier-
archical structure that allows for guiding the user
through a more algorithmic approach. There is
also a capacity to provide assistance with dosing
calculations that do not exist in the paper world.
Education remains of key importance for both
methods.
MONITOR THE USE AND EFFECTIVENESS OF YOUR
PROTOCOLS AND ORDER SETS
Creating and implementing protocols, order sets,
and other tools is not the end of the journey to
improve care. It is important to monitor order set
utilization, insulin use patterns, and parameters
measuring glycemic control and hypoglycemia, as
outlined in more detail in another article in this
supplement.16 In addition to summary data every
month or so, we recommend daily reports that
spur action in near real time. Triggers such as
uncontrolled hyperglycemia, markedly elevated
HbA1c levels, and nonphysiologic insulin regi-
mens should initiate consultation, extra diabetes
education, or referral to a glucose control team. If
appropriate consultation is not readily available,
the glycemic control steering group should lobby
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the administration to bolster this capability. Quali-
tative feedback from the frontline caregivers, as
well as this quantitative data, can assist the local
glycemic control champions in designing even
more effective protocols, order sets, focused edu-
cational efforts, and concurrent mitigation of sub-
optimal care.
CONCLUSION
Diabetes, hyperglycemia, and iatrogenic hypogly-
cemia are common and important conditions
affecting the non–critically ill inpatient. Interven-
tional trials to validate the recommended non–
critical care unit glycemic targets are needed.
Although there is a growing consensus on best
practices to care for these patients, numerous bar-
riers and the complexity of caring for inpatients
hamper the reliability of best practice delivery.
Institutional protocols and protocol driven subcu-
taneous insulin orders, when implemented with
the strategies outlined here, can be the key to
delivering these best practices more reliably.
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